First Line Therapy in Multiple Myeloma: VAD vs Bortezomib -Dexamethasone
| العنوان: | First Line Therapy in Multiple Myeloma: VAD vs Bortezomib -Dexamethasone |
|---|---|
| المؤلفون: | Constantin Luca, Adina Ioana Bucur, Bianca Cerbu, Hortensia Ionita, Dan Costachescu, Ema-Cristina Borsi, Ovidiu Potre Oncu, Ioana Ionita, Cristina Potre Oncu |
| المصدر: | Revista de Chimie. 70:1017-1022 |
| بيانات النشر: | Revista de Chimie SRL, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, business.industry, Materials Science (miscellaneous), Process Chemistry and Technology, General Engineering, General Chemistry, General Medicine, medicine.disease, General Biochemistry, Genetics and Molecular Biology, First line therapy, Internal medicine, Materials Chemistry, medicine, General Pharmacology, Toxicology and Pharmaceutics, business, Multiple myeloma, Bortezomib/dexamethasone |
| الوصف: | Multiple myeloma (MM) is typically sensitive to a range of cytotoxic agents, both as initial therapy and as relapsed disease treatment. Unfortunately, the responses are transient, and MM is not considered curable with the current approaches. This paper aims to assess the response to first line treatment of patients included in the study and their correlation with the negative prognostic factors in multiple myeloma: age over 60 years, male gender, anemia, hypercalcemia, elevated levels of creatinine, Beta 2 microglobulin, hypoalbuminemia and Bence-Jones proteins type. The study was conducted on a group of 105 patients admitted to the Hematology Department of the Municipal Emergency Clinical Hospital of Timisoara from 01 January 2013 until 31 December 2017. Twenty-seven patients received VAD regimen, while 78 underwent Bortezomib + Dexamethasone regimen as fist line therapy. When analyzing anthropometrical data, different gender distribution in the two groups of patients is seen, while a higher percentage of patients over 60 years is observed in both groups, with 77.7% in the VAD group (21 out of 27 patients) and 56.4% in the group treated with Bortezomib + Dexamethasone (44 out of 78 patients). Only some of the factors analyzed in our study statistically significantly influenced the response to treatment and the duration of survival, i.e.: age over 60 years, hemoglobin [10g/dL, platelets under 150000/mm3, creatinine ]2mg/dL, serum calcium ]10mg / dL, increased C-reactive protein, low serum albumin levels, high levels of Beta 2 microglobulin, total serum protein, as well as presence of cells in the peripheral smear. Defining a panel of negative prognostic factors that influence the evolution and response to multiple myeloma treatment would allow for tailoring of personalized therapies for each patient. |
| تدمد: | 2668-8212 0034-7752 |
| DOI: | 10.37358/rc.19.3.7053 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::0eaf131441be2a3e18027c0ae5fbea5f https://doi.org/10.37358/rc.19.3.7053 |
| رقم الانضمام: | edsair.doi...........0eaf131441be2a3e18027c0ae5fbea5f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 26688212 00347752 |
|---|---|
| DOI: | 10.37358/rc.19.3.7053 |